The researchers envision that their discovery may eventually result in a test that contributes to more personalized treatment of metastatic castration-resistant prostate cancer.
Read More
The test helps clinicians to determine whether a patient with metastatic castration-resistant prostate cancer will benefit most from taxane chemotherapy or androgen-directed therapeutics.
Read More
In a validation study, researchers found that the new test had a sensitivity of 85% and specificity of 75%—both results superior to tests currently on the market.
Read More
Combined with enhancing multiparametric MRI, the test could spare men from prostate biopsy.
Read More
Global congress features multiple clinical study abstracts on the SelectMDx liquid biopsy test for prostate cancer.
Read More